Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy in Metastatic Melanoma
NCT00863330Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2009
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC101 TIL + pembrolizumab in melanoma, sponsored by Wake Forest University Health Sciences. Started Feb 2009; status: terminated.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00863330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00863330.